Deals and Financings • Shanghai United Imaging Healthcare, which makes high-end medical imaging machines, closed a $500 million A financing at a $5 billion valuation;• Shanghai Fosun Pharma signed a $106 million deal with Palatin for China rights to a female sexual desire disorder treatment;• Harbour BioMed, a China-US biopharma, closed an $81 million agreement with Korea’s HanAll Biopharma to develop two of HanAll’s novel biologics in China;• Wellem raised $30 million in a Series B Round to expand its network of franchised private pediatric clinics in China;• Suzhou Basecare Medical Device closed a $15.3 million B financing for its assisted reproduction diagnostic products;• Ennovabio, a Shanghai pharma developing a brain cancer candidate, raised $10 million in a pre-A funding;• Spineology of St. Paul, Minnesota announced a $5 million investment from Hermed Capital of Shanghai for its novel spinal devices;• China Resources Holdings invested $4.6 million in Converd Company, a Hangzhou company developing oncolytic virus products;• Grid Therapeutics of Durham, North Carolina completed an A financing from Singapore’s Longview to develop its cancer immunotherapy;• HitGen. the Chengdu-Houston lead-generation CRO, signed a deal to discover novel drug leads for Japan’s Takeda Pharma.
